Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10858664 | 0.79 | AOC3 (0.51) | AOC3FFAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL7926083 | 0.78 | AOC3 (0.44) | AOC3FFAR1ACP3 | |
| SCHEMBL16399016 | 0.78 | ENPP2 (0.39) | FFAR1 | |
| SCHEMBL6203322 | 0.78 | AOC3 (0.53) | AOC3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL11080040 | 0.78 | HPGD (0.41) | AOC3FFAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5377867 | 0.77 | HIF1A (0.49) | OPRM1SLC6A3 | |
| SCHEMBL31175995 | 0.77 | IDO1 (0.43) | OPRM1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8309641 | 0.77 | PTGS2 (0.37) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3141582 | 0.77 | IDO1 (0.43) | OPRM1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3871619 | 0.77 | CYP3A4 (0.48) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104230879-B | A kind of 2-((4R, 6S)-6-formoxyl-2,2-disubstituted-1,3-dioxane-4-base) acetas preparation method | 新发药业有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-104230879-A | Simple and convenient preparation method of 2-((4R,6S)-6-formyl-2,2-disubstituted-1,3-dioxane-4-yl)acetate | XINFA PHARMACEUTICAL CO LTD | 2014-12-24 | — | — | CN | disclosed |
| CN-100406462-C | Method for producing formylphenylboronic acids | CLARIANT GMBH (DE) | 2008-07-30 | — | — | CN | disclosed |
| CN-1630659-A | Method for producing formylphenylboronic acids | CLARIANT GMBH (DE) | 2005-06-22 | — | — | CN | disclosed |
| EP-1343792-B1 | METHOD FOR PRODUCING FORMYLPHENYLBORONIC ACIDS | CLARIANT GMBH (DE) | 2005-02-02 | — | — | EP | disclosed |
| US-6833470-B2 | Reaction of protected chlorobenzaldehydes with lithium in an inert solvent and reacting lithiated product with a trihalo-, trialkoxy-, trialkylthio- or tris(dialkylamino)- borane | CLARIANT GMBH (DE) | 2004-12-21 | — | — | US | disclosed |
| US-20040049050-A1 | Method for producing formylphenylboronic acids | EUTICALS GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| EP-1343792-A1 | METHOD FOR PRODUCING FORMYLPHENYLBORONIC ACIDS | Clariant GmbH (DE) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002048155-A1 | METHOD FOR PRODUCING FORMYLPHENYLBORONIC ACIDS | CLARIANT GMBH (DE) | 2002-06-20 | — | — | WO | disclosed |
| EP-0968177-B1 | METHOD FOR PRODUCING AROMATIC NITRILES | BAYER AG (DE) | 2002-01-23 | — | — | EP | disclosed |
| US-6162942-A | Method for producing aromatic nitriles | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-19 | — | — | US | disclosed |
| EP-0968177-A1 | METHOD FOR PRODUCING AROMATIC NITRILES | Bayer Aktiengesellschaft (DE) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998037058-A1 | METHOD FOR PRODUCING AROMATIC NITRILES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-08-27 | — | — | WO | disclosed |
| US-4629737-A | HYPOGLYCEMIC AGENTS; DIETETICS | BEECHAM GROUP P.L.C. (GB) | 1986-12-16 | — | — | US | disclosed |
| EP-0099707-B1 | 2-AMINOETHYL ETHER DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1986-12-10 | — | — | EP | disclosed |
| EP-0099707-A1 | 2-Aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1984-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049050-A1 | Method for producing formylphenylboronic acids | MAOB, BLVRB, FOSB | AOC3 708/4885FFAR1 675/4885OPRM1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.